| abstract |
COMBINATION OF ORGANIC COMPOUNDS. It is a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising: i) a DPP IV inhibitor or a pharmaceutically acceptable salt thereof, and ii) at least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such a combination for the prevention, progression retardation or treatment of a disease or condition selected from insulin resistance, impaired glucose metabolism (IGT), impaired glucose tolerance conditions, plasma glucose conditions. impaired fasting, diabetes particularly type 1 or type 2 diabetes mellitus, obesity, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, erectile dysfunction, premenstrual syndrome, coronary heart disease, hypertension, angina pectoris , myocardial infarction, stroke, vascular restenosis, connective tissue and skin disorders, foot ulcers and ulcerative colitis, endothelial dysfunction and compromised vascular compliance, and vascular events, cardiovascular morbidity or mortality associated with diabetes (eg, type I or II) or IGT . |